Dr. Jimin Shi 施继敏
Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Hematopoietic stem cell transplantation, leukemia, malignant lymphoma, multiple myeloma, and myelodysplastic syndromes.
Dr. Shi holds a medical doctorate and has 20 years of clinical experience. Dr. Shi has independently performed over 100 hematopoietic stem cell transplants. Research includes three National Natural Science Foundation projects. Dr. Shi has published over 20 papers, including 10 SCI-indexed articles, and co-authored two books. Awards include provincial science and technology progress prizes.
Professional roles
- Member, Chinese Medical Association
- Member, Infection Group of the 11th Hematology Branch, Chinese Medical Association
- Vice Chair and Secretary, Hematology Branch of Zhejiang Immunological Society
- Standing Committee Member, Hematology and Lymphology Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Shi Jimin). Papers usually list the name as Jimin Shi or Shi J.
Selected publications
109 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Hematol, 2025 (senior author): Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogenetics, IKZF1 deletions and minimal residual disease. PubMed 39843812
- Bone Marrow Transplant, 2025 (senior author): Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?. PubMed 39627346
- Ann Hematol, 2024 (senior author): Impact of additional cytogenetic aberrations at diagnosis on prognosis of adults patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: a retrospective analysis. PubMed 38963448
- Cell Transplant, 2024 (senior author): Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors. PubMed 38270130
- Am J Hematol, 2023 (senior author): Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. PubMed 37728241
- Ann Hematol, 2022 (senior author): Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. PubMed 36318288
- Infect Drug Resist, 2022 (senior author): Clinical Characteristics, Microbiology, and Risk Factors for Mortality of Pre-Engraftment and Post-Engraftment Bloodstream Infection in Hematopoietic Stem Cell Transplantation Recipients. PubMed 36465805
- Front Oncol, 2021 (senior author): Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. PubMed 33996600
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion